NASDAQ:HZNP

Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

$100.88

+0.59 (+0.59%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $100.17
▼
$104.35
50-Day Range: $61.58
▼
$100.88
52-Week Range: $57.84
▼
$117.49

Volume: 4.35 million shs
Average Volume: 2.33 million shs
Market Capitalization: $22.86 billion

P/E Ratio: 41.34
Dividend Yield: N/A
Price Target: $105.00

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 6.1% Upside
$107.00 Price Target
Short Interest: Healthy
3.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.35
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 24.34%
From $4.15 to $5.16 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

318th out of 1,047 stocks

Pharmaceutical Preparations Industry

134th out of 512 stocks

1.4

Analyst's Opinion

Consensus Rating
Horizon Therapeutics Public has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $107.00, Horizon Therapeutics Public has a forecasted upside of 6.1% from its current price of $100.88.
Amount of Analyst Coverage
Horizon Therapeutics Public has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.11% of the float of Horizon Therapeutics Public has been sold short.
Short Interest Ratio / Days to Cover
Horizon Therapeutics Public has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Horizon Therapeutics Public has recently decreased by 7.05%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Horizon Therapeutics Public does not currently pay a dividend.
Dividend Growth
Horizon Therapeutics Public does not have a long track record of dividend growth.

3.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Horizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Horizon Therapeutics Public is -2.61.

3.0

News and Social Media Coverage

News Sentiment
Horizon Therapeutics Public has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Horizon Therapeutics Public this week, compared to 2 articles on an average week.
Search Interest
32 people have searched for HZNP on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
MarketBeat Follows
9 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.50% of the stock of Horizon Therapeutics Public is held by insiders.
Percentage Held by Institutions
89.06% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Horizon Therapeutics Public are expected to grow by 24.34% in the coming year, from $4.15 to $5.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Horizon Therapeutics Public is 41.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of Horizon Therapeutics Public is 41.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 152.46.
Price to Earnings Growth Ratio
Horizon Therapeutics Public has a PEG Ratio of 1.57. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Horizon Therapeutics Public has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Stock News Headlines

December 1, 2022 | americanbankingnews.com

Stock Traders Purchase Large Volume of Put Options on Horizon Therapeutics Public (NASDAQ:HZNP)

November 30, 2022 | msn.com

$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today

November 30, 2022 | msn.com

Horizon Therapeutics in separate sale talks with Amgen, Sanofi and J&J

November 29, 2022 | msn.com

Drug company Horizon Therapeutics confirms it is in talks with potential suitors

November 24, 2022 | americanbankingnews.com

Horizon Therapeutics Public (NASDAQ:HZNP) Upgraded to "B-" by TheStreet

November 24, 2022 | americanbankingnews.com

Horizon Therapeutics Public (NASDAQ:HZNP) Rating Increased to B- at TheStreet

November 23, 2022 | finance.yahoo.com

Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?

November 16, 2022 | finance.yahoo.com

Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation

November 16, 2022 | finance.yahoo.com

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

November 10, 2022 | finance.yahoo.com

Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November

November 9, 2022 | finance.yahoo.com

Why Horizon Therapeutics Public Limited Company (HZNP) Declined in the Third Quarter?

November 8, 2022 | finance.yahoo.com

Horizon Therapeutics Third Quarter 2022 Earnings: Beats Expectations

November 8, 2022 | finance.yahoo.com

Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial

November 5, 2022 | finance.yahoo.com

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

November 2, 2022 | benzinga.com

This Is What Whales Are Betting On Horizon Therapeutics

November 2, 2022 | finance.yahoo.com

Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

November 1, 2022 | finance.yahoo.com

Horizon Therapeutics plc Named to the Seramount Inclusion Index

October 27, 2022 | finance.yahoo.com

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

October 26, 2022 | finance.yahoo.com

New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks

October 22, 2022 | finance.yahoo.com

New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment

October 13, 2022 | finance.yahoo.com

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

October 12, 2022 | finance.yahoo.com

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022

October 7, 2022 | seekingalpha.com

Horizon Therapeutics cuts FY adj. EBITDA guidance to reflect new milestone related expense

October 6, 2022 | finance.yahoo.com

Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces

October 6, 2022 | finance.yahoo.com

Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings: 11/03/2021
Today: 12/02/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:HZNP
CUSIP: 44047T10
CIK: 1492426
Web: www.horizontherapeutics.com
Phone: (531) 772-2100
Fax: 224-383-3001
Employees: 1,890
Year Founded: 2008

Price Target and Rating

Average Stock Price Forecast: $107.00
High Stock Price Forecast: $144.00
Low Stock Price Forecast: $71.00
Forecasted Upside/Downside: +4.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.44
Trailing P/E Ratio: 41.34
Forward P/E Ratio: 24.31
P/E Growth: 1.57
Net Income: $534.49 million
Net Margins: 15.51%
Pretax Margin: 15.77%
Return on Equity: 24.59%
Return on Assets: 13.56%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 3.96
Quick Ratio: 3.74

Sales & Book Value

Annual Sales: $3.23 billion
Price / Sales: 7.09
Cash Flow: $8.25 per share
Price / Cash Flow: 12.23
Book Value: $22.21 per share
Price / Book: 4.54

Miscellaneous

Outstanding Shares: 226,621,000
Free Float: 220,955,000
Market Cap: $22.86 billion
Optionable: Optionable
Beta: 1.09

Social Links

Key Executives

Mr. Timothy P. Walbert (Age 55)
Chairman, Pres & CEO
Comp: $5.54M

Dr. Jeffrey W. Sherman F.A.C.P. (Age 67)
FACP, M.D., Exec. VP & Chief Medical Officer
Comp: $1.65M

Mr. Paul W. Hoelscher (Age 57)
Advisor
Comp: $2.07M

Mr. Andy Pasternak (Age 51)
Exec. VP & Chief Strategy Officer
Comp: $1.67M

Mr. Aaron L. Cox (Age 39)
Exec. VP of Fin. & CFO

Mr. Miles W. McHugh (Age 57)
Chief Accounting Officer & Sr. VP

Ms. Tina E. Ventura
Sr. VP & Chief Investor Relations Officer

Mr. Sean M. Clayton J.D. (Age 43)
Exec. VP & Gen. Counsel

Mr. Geoffrey M. Curtis (Age 47)
Exec. VP of Corp. Affairs & Chief Communications Officer

Ms. Jane Gonnerman
Group VP of Corp. Devel., Chief of Staff & Office of the CEO

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HZNP shares.
View HZNP analyst ratings or view top-rated stocks.
What is Horizon Therapeutics Public's stock price forecast for 2023?: 9 Wall Street analysts have issued 1 year price objectives for Horizon Therapeutics Public's shares. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they predict the company's stock price to reach $107.00 in the next twelve months. This suggests a possible upside of 6.1% from the stock's current price.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.
How have HZNP shares performed in 2022?: Horizon Therapeutics Public's stock was trading at $107.76 at the start of the year. Since then, HZNP shares have decreased by 6.4% and is now trading at $100.88.
View the best growth stocks for 2022 here.
When is Horizon Therapeutics Public's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our HZNP earnings forecast.
How were Horizon Therapeutics Public's earnings last quarter?: Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.21. The biopharmaceutical company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $979.49 million. Horizon Therapeutics Public had a net margin of 15.51% and a trailing twelve-month return on equity of 24.59%. The business's revenue was up 62.9% compared to the same quarter last year. During the same period last year, the firm earned $1.74 earnings per share.
What guidance has Horizon Therapeutics Public issued on next quarter's earnings?: Horizon Therapeutics Public updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.59 billion-$3.61 billion, compared to the consensus revenue estimate of $3.56 billion.
What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?: 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).
What is Horizon Therapeutics Public's stock symbol?: Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."
Who are Horizon Therapeutics Public's major shareholders?: Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.39%), BlackRock Inc. (6.89%), Nuveen Asset Management LLC (3.07%), Paulson & CO. Inc. (2.69%), State Street Corp (2.53%) and Barclays PLC (1.67%). Insiders that own company stock include Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.
How do I buy shares of Horizon Therapeutics Public?: Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Horizon Therapeutics Public's stock price today?: One share of HZNP stock can currently be purchased for approximately $100.88.
How much money does Horizon Therapeutics Public make?: Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $22.86 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $2.44 on an earnings per share basis.
How many employees does Horizon Therapeutics Public have?: The company employs 1,890 workers across the globe.
Does Horizon Therapeutics Public have any subsidiaries?: The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..
Read More
How can I contact Horizon Therapeutics Public?: Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial